NVCT Stock Analysis: Buy, Sell, or Hold?
NVCT - Nuvectis Pharma, Inc. Common Stock
$12.55
0.51 (4.24%)
▲
5d:
+21.61%
30d:
+47.65%
90d:
+42.61%
WAIT
LOW Confidence
Analysis Updated: May 13, 2026 12:00 AM ET
Earnings: May 05, 2026
0d
Get Alerted When NVCT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: NVCT is 20.0% above its trading range ($10.46). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: NVCT is 20.0% above its trading range ($10.46). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: NVCT is currently trading at $12.55, which is considered extended relative to its 30-day fair value range of $7.93 to $10.46.
Technical Outlook: Technically, NVCT is in a uptrend. Immediate support is located at $8.42, while resistance sits at $13.34. The stock is showing strong short-term momentum, up 4.2% recently.
Market Sentiment: NVCT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $16.80 (+39.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NVCT is in a uptrend. Immediate support is located at $8.42, while resistance sits at $13.34. The stock is showing strong short-term momentum, up 4.2% recently.
Market Sentiment: NVCT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $16.80 (+39.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$7.93 -
$10.46
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BEARISH: Price significantly overextended (+20.0% above its trading range)
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.2%)
- BULLISH: Trading 39.5% below Wall St target ($16.80)
- WARNING: Recommendation downgraded due to 20.0% overvaluation
Trading Range Analysis
30-Day Trading Range
$7.93 -
$10.46
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$1.71
(13.6%)
Support & Resistance Levels
Support Level
$8.42
Resistance Level
$13.34
Current Trend
Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.23
Wall Street Target
$16.80
(+39.5%)
Share & Embed Analysis
Last updated: May 14, 2026 1:42 PM ET
Data refreshes hourly during market hours. Next update: 2:42 PM
Data refreshes hourly during market hours. Next update: 2:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NVCT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 55 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$73 | 54 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 58 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 59 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
